• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

BDKRB2 Polyklonaler Antikörper

BDKRB2 Polyklonal Antikörper für WB, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, Indirect ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 17847-1-PBS

Synonyme

BK-2 receptor, BK2, BK 2 receptor, BK 2, B2R

Filter:
  • Western Blot (WB) analysis of various lysates using BDKRB2 Polyclonal antibody (17847-1-AP)

    WB analysis using 17847-1-AP (same clone as 17847-1-PBS)

    Various lysates were subjected to SDS PAGE followed by western blot with 17847-1-AP (BDKRB2 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 17847-1-PBS in a different storage buffer formulation.

Geprüfte Anwendungen

Produktinformation

17847-1-PBS bindet in WB, Indirect ELISA BDKRB2 und zeigt Reaktivität mit human

Getestete Reaktivität human
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen BDKRB2 fusion protein Ag12268
Vollständiger Name bradykinin receptor B2
Berechnetes Molekulargewicht 391 aa, 44 kDa
Beobachtetes Molekulargewicht44 kDa
GenBank-ZugangsnummerBC074895
Gene symbol BDKRB2
Gene ID (NCBI) 624
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

The BK system is important in cancer occurrence and progression. It stimulates cell proliferation, migration, and angiogenesis, contributing to tumor progression. As a vital receptor of bradykinin, BDKRB2 (Bradykinin receptor B2) has been widely reported in a range of malignancies, including cervical cancer, triple-negative breast cancer, hepatocellular carcinoma (HCC), gastric cancer, colorectal cancer, prostate cancer, bladder cancer, head and neck squamous cell carcinomas, and chondrosarcoma (PMID: 33686021).